|
|
|
|
|
HONG KONG, Mar 19, 2016 - (ACN Newswire) - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today released its annual report of 2015. According to the data, from January to December 2015, Shanghai Pharmaceutical's operating revenue was RMB105.517 billion, up by 14.20% on a YOY basis. Net profit attributable to the equity holders of listed Company was RMB2.877 billion, a YOY increase of 11.03%. Basic earnings per share amounted to RMB1.0699 and basic earnings per share after deducting non-recurring profits and losses were RMB0.9410, up by 17.08%, fulfilled the budget target for the year of 2015.
In pharmaceutical research and development costs, the total amount of research and development (the "R&D") investment was RMB617.6908 million (excluding the investment in the construction of interim test bases of the Company), accounting for 5.22% of manufacturing sales income of the Company. Among them, 26.98% was invested in R&D of innovative drugs, 23.46% was invested in the R&D of generic drugs and 49.56% was invested in the secondary development of existing products. Sales revenue from the Company's new products launched through the R&D amounted to RMB1.707 billion, representing 14% of the Company's manufacturing sales revenue. Shanghai Pharmaceuticals will continue to optimize the R&D system, improve the efficiency of R&D, strengthen the approval and process management of R&D project, initiate the construction of scientific research management information system in the Group, promote implementation of project manager system and improve the enthusiasm of the R&D personnel and the efficiency of R&D of the whole projects; strengthen the open and cooperation, optimize the R&D model; continue to promote base construction which integrated R&D, pre-production and industrialization exploitation of the chemical raw medicine and high-end preparation as a whole to positively solve the "bottleneck" problem about the allocation of resources in the industrialization process of achievements.
In pharmaceutical manufacturing business, the Company's sales revenue from the pharmaceutical business was RMB11.824 billion, representing a growth of 6.49% as compared with the corresponding period of last year; its gross profit margin was 49.72%, a YOY increase of 1.49 percentage point. The operating profit margin after deducting sales and administration costs was 12.44%, a YOY increase of 0.42 percentage point. Sales revenue of 60 key products reached RMB6.79 billion, up by 12.52% on a YOY basis, accounting for 57.43% of the revenue from industrial sales. The gross profit margin of the key products was 67.04%. 24 products attained the product sales revenue of over RMB100 million. The Company will continue to implement its strategy to focus on key products of chemical drugs, biological drugs and medical treatment fields in which it has an advantage. In the meanwhile, with respect to the traditional Chinese medicine, the Company will build a new total-industry chain by grasping the historical development opportunity; optimize the R&D investment mechanism, improve the contribution of new products, strengthen the role of the marketing center and expand the depth and width of the management mode of one policy for one product, as well as optimize the layout of industrial bases, promote the six-sigma management, and accelerate the improvement of industry energy level.
In respect of pharmaceutical services business, the Company's sales revenue from pharmaceutical distribution business was RMB93.717 billion, representing an increase of 15.47% on a YOY basis, with a gross profit margin of 6.02%. The costs of sales and administration accounted for 3.44%, a YOY decrease of 0.12 percentage point. The operating profit margin after deducting the sales and administration expenses was 2.58%, a YOY increase of 0.08 percentage point. The sales revenue from the Company's pharmaceutical retail was RMB4.795 billion, a YOY increase of 13.68%; gross profit margin was 15.64%; and operating profit margin after deducting sales and administration costs was 1.50%. In October 2015, SPH Cloud Health completed the integration of DTP business platform, by the end of 2015, the sales income was approximately RMB 606 million. In 2015, the DTP business covered 24 cities, a total of 30 DTP designated pharmacies, achieved annual sales income of RMB 2.478 billion. Taking a step forward, Shanghai Pharmaceuticals will strengthen its competitive advantage in major areas, accelerate its expansion in strategic regions, insist on optimizing its national business network, invest more into the markets at the grass-root level and B2B business, strengthen the interaction between industry and commerce and business mode innovation, promote the extended supply chain services, and promote the lean operation level of the supply chain. The Company will also build a three-layer network including online E-commerce platform and offline network through internal optimization and external expansion to create a pharmaceutical retail mode integrating online and offline services. Meanwhile, the Company will focus on the exploration of the new growth point-grand health business, which aims to improve the new mode, and actively explore new business areas. Shanghai Pharmaceuticals strives to provide consumers with a better purchasing experience of medicines in O2O retail mode, sustain a high quality, convenient pharmaceutical services, and achieve its business value and win-win situation for the society.
Topic: Press release summary
Source: Shanghai Pharmaceuticals
Sectors: Daily Finance, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
